OTCMKTS:RNUGFReNeuron Group Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ReNeuron Group Plc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.78 0.00 (0.00 %) (As of 07/7/2020 04:00 PM ET) Add Compare Share Today's Range$1.78Now: $1.78▼$1.7850-Day Range$1.75MA: $1.79▼$1.9852-Week Range$0.95Now: $1.78▼$3.29VolumeN/AAverage Volume244 shsMarket Capitalization$56.66 millionP/E RatioN/ADividend YieldN/ABeta-26.14 ProfileAnalyst RatingsAdvanced ChartCompetitorsHeadlinesSocial Media ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia. It is also involved in developing human retinal progenitor cell candidate, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, a blindness-causing disease of the retina, as well as that is in Phase I clinical trial to treat cone-rod dystrophy, an inherited eye disorder; and CTX-derived exosomes, which are nanoparticles released by cells containing various active proteins and microRNAs. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingReNeuron Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, ReNeuron Group has a potential upside of 237.1% from its current price of $1.78.Amount of Analyst CoverageReNeuron Group has received no research coverage in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesReNeuron Group has received 99 “outperform” votes. (Add your “outperform” vote.)Underperform VotesReNeuron Group has received 97 “underperform” votes. (Add your “underperform” vote.)Community SentimentReNeuron Group has received 50.51% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ReNeuron Group and other stocks. Vote “Outperform” if you believe RNUGF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RNUGF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldReNeuron Group does not currently pay a dividend.Dividend GrowthReNeuron Group does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ReNeuron Group insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ReNeuron Group are expected to decrease in the coming year, from ($0.63) to ($0.73) per share. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.20 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Private households Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:RNUGF Previous SymbolNASDAQ:RNUGF CUSIPN/A CIKN/A Webwww.reneuron.com Phone44-0-20-3819-8400Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$60,000.00 Price / Sales944.29 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees62 Outstanding Shares31,830,000Market Cap$56.66 million Next Earnings DateN/A OptionableNot Optionable OTC:RNUGF Rates by TradingView Receive RNUGF News and Ratings via Email Sign-up to receive the latest news and ratings for RNUGF and its competitors with MarketBeat's FREE daily newsletter. ReNeuron Group (OTCMKTS:RNUGF) Frequently Asked Questions How has ReNeuron Group's stock been impacted by COVID-19 (Coronavirus)? ReNeuron Group's stock was trading at $1.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RNUGF shares have increased by 1.7% and is now trading at $1.78. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of ReNeuron Group? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ReNeuron Group in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ReNeuron Group. What price target have analysts set for RNUGF? 1 Wall Street analysts have issued twelve-month price objectives for ReNeuron Group's stock. Their forecasts range from $6.00 to $6.00. On average, they expect ReNeuron Group's stock price to reach $6.00 in the next year. This suggests a possible upside of 237.1% from the stock's current price. View analysts' price targets for ReNeuron Group. Has ReNeuron Group been receiving favorable news coverage? Media stories about RNUGF stock have been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ReNeuron Group earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about ReNeuron Group. Who are some of ReNeuron Group's key competitors? Some companies that are related to ReNeuron Group include Poxel (PXXLF), EAGLE POINT CR/COM (ECC), TAIWAN FD INC/SH (TWN), Integra Resrcs (IRRZF), SUPERDRY PLC/ADR (SEPGY), NicOx (NICXF), FOXTONS GRP PLC/ADR (FXTGY), ESPRIT HOLDINGS/S (ESPGY), Paladin Energy (PALAF), Bank Of Princeton (BPRN), NOBLE GRP LTD/ADR (NOBGY), Restaurant Group (RSTGF), 5N Plus (FPLSF), Green Organic Dutchman (TGODF) and ADOCIA/S (ADOCY). View all competitors. Who are ReNeuron Group's key executives? ReNeuron Group's management team includes the following people: Mr. Olav Hellebø, CEO & Director (Age 54)Mr. Michael E. Hunt, CFO, Sec. & Exec. Director (Age 56)Dr. John David Sinden BA, MA, Ph.D., Founder & Chief Scientific Officer (Age 68)Dr. Randolph Corteling, Head of ResearchMr. Shaun Stapleton BSc (Hons) MTOPRA, Head of Regulatory Affairs What is ReNeuron Group's stock symbol? ReNeuron Group trades on the OTCMKTS under the ticker symbol "RNUGF." How do I buy shares of ReNeuron Group? Shares of RNUGF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is ReNeuron Group's stock price today? One share of RNUGF stock can currently be purchased for approximately $1.78. How big of a company is ReNeuron Group? ReNeuron Group has a market capitalization of $56.66 million and generates $60,000.00 in revenue each year. ReNeuron Group employs 62 workers across the globe. What is ReNeuron Group's official website? The official website for ReNeuron Group is www.reneuron.com. How can I contact ReNeuron Group? ReNeuron Group's mailing address is Pencoed Business Park Bridgend, Pencoed X0, CF35 5HY. The company can be reached via phone at 44-0-20-3819-8400. This page was last updated on 7/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
